Elicio Therapeutics Inc (ELTX)
8.41
-0.44
(-4.97%)
USD |
NASDAQ |
May 24, 16:00
8.43
+0.02
(+0.24%)
After-Hours: 20:00
Elicio Therapeutics SG&A Expense (Quarterly): 2.682M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.682M |
| December 31, 2023 | 3.235M |
| September 30, 2023 | 3.507M |
| June 30, 2023 | 2.833M |
| March 31, 2023 | 2.321M |
| Date | Value |
|---|---|
| December 31, 2022 | 1.671M |
| September 30, 2022 | 1.177M |
| June 30, 2022 | 1.191M |
| March 31, 2021 | 1.639M |
| March 31, 2020 | 0.6338M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.6338M
Minimum
Mar 2020
3.507M
Maximum
Sep 2023
2.089M
Average
1.996M
Median
SG&A Expense (Quarterly) Benchmarks
| Immuneering Corp | 4.116M |
| Outlook Therapeutics Inc | 5.431M |
| Amylyx Pharmaceuticals Inc | 57.76M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |